Biomea Fusion Clears Chronic Tox Hurdle for Icovamenib, Enabling Extended Clinical Dosing in Diabetes Trials

Completion of chronic toxicology studies for icovamenib removes a key nonclinical constraint that had capped clinical dosing at 12 weeks, with Biomea Fusion now holding the preclinical package needed to support longer-duration IND amendments across its diabetes and obesity programs. For CMC and regulatory affairs teams tracking the menin-inhibitor space, the two-species chronic tox clearance signals an imminent protocol evolution that will require updated nonclinical summaries and revised risk assessments in regulatory submissions.

The chronic tox findings demonstrated a favorable safety profile consistent with prior preclinical and clinical data, and the broader clinical safety record now covers more than 400 dosed subjects. That accumulated exposure dataset strengthens the benefit-risk narrative for 21 CFR Part 312 IND amendments and any corresponding ICH M3(R2) alignment required for chronic dosing justification. Biomea has not disclosed the specific duration supported by the completed studies, a detail that will carry weight when the full dataset is presented at a forthcoming scientific conference.

On the clinical side, 52-week follow-up data from the Phase II COVALENT-112 trial in type 1 diabetes showed a 52% increase from baseline in mean C-peptide AUC at Week 12 post-dosing in recently diagnosed patients (0-3 years) receiving icovamenib 200 mg, with the effect largely preserved through Week 52 (approximately 7% decline from baseline). C-peptide preservation was also observed in patients diagnosed between 3 and 15 years. The company characterizes the findings as supporting menin as a mechanistic target across both T1D and T2D, and plans to initiate an investigator-sponsored Phase II trial in T1D in collaboration with academic institutions.

Two Phase II T2D trials are now enrolling: COVALENT-211, targeting insulin-deficient T2D patients not at glycemic goal on standard of care, and COVALENT-212, targeting T2D patients on GLP-1 receptor agonist-based therapy. Both carry 26-week primary endpoints, with topline data expected in Q4 2026. The GLP-1 combination arm is particularly relevant given the current regulatory and commercial scrutiny on combination approaches in the obesity and metabolic disease space. The Phase I GLP-131 (BMF-650) obesity trial remains on track, with initial 28-day weight reduction data anticipated in Q2 2026.

With cash runway projected into Q1 2027, the pace of IND amendments and protocol updates across three active programs will test the operational bandwidth of Biomea's regulatory and quality functions through the remainder of the year.

Source: Biomea Fusion, Inc. via GlobeNewswire, May 11, 2026.